Reply to G Taubes, MI Friedman, and V Torres-Carot et al.

Kevin D. Hall; I. Sadaf Farooqi; Jeffery M. Friedman; Samuel Klein; Ruth J.F. Loos; David J. Mangelsdorf; Stephen O’Rahilly; Eric Ravussin; Leanne M. Redman; Donna H. Ryan; John R. Speakman; Deirdre K. Tobias

doi:10.1093/ajcn/nqac163

Reply to G Taubes, MI Friedman, and V Torres-Carot et al.

Kevin D. Hall
, I. Sadaf Farooqi
, Jeffery M. Friedman
, Samuel Klein
, Ruth J.F. Loos
, David J. Mangelsdorf
, Stephen O’Rahilly
, Eric Ravussin
, Leanne M. Redman
, Donna H. Ryan
, John R. Speakman
, Deirdre K. Tobias

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	614-616
Number of pages	3
Journal	American Journal of Clinical Nutrition
Volume	116
Issue number	2
DOIs	https://doi.org/10.1093/ajcn/nqac163
State	Published - Aug 1 2022

Access to Document

10.1093/ajcn/nqac163

Cite this

@article{4548c67d5eae44d1889e2e9ea6cac2f6,

title = "Reply to G Taubes, MI Friedman, and V Torres-Carot et al.",

author = "Hall, \{Kevin D.\} and Farooqi, \{I. Sadaf\} and Friedman, \{Jeffery M.\} and Samuel Klein and Loos, \{Ruth J.F.\} and Mangelsdorf, \{David J.\} and Stephen O{\textquoteright}Rahilly and Eric Ravussin and Redman, \{Leanne M.\} and Ryan, \{Donna H.\} and Speakman, \{John R.\} and Tobias, \{Deirdre K.\}",

note = "Funding Information: Supported by NIH grant 1ZIADK013037 (to KDH). KDH has participated in several debates with David S Ludwig on theories of obesity and has received funding from the Nutrition Science Initiative to test predictions of the CIM. JMF reports royalty payments for leptin for the treatment of lipodystrophy. SK serves as a scientific consultant for Altimmune, Janssen, and B2M and has a sponsored research agreement with Janssen. SOR receives remuneration for scientific advice from Pfizer, AstraZeneca, and ThirdRock Ventures. DHR reports personal fees from Altimmune, Amgen, Gila Therapeutics, Phenomix, Quintiles, Rhythm, YSOPIA, Zealand, Lilly, and Wondr Health, and Roman Health, and personal fees and nonfinancial support from Boeringer Ingelheim, Calibrate, Epitomee, IFA Celtic, Janssen, Novo Nordisk, real appeal (United Health Care), Sanofi, Scientific Intake, and Xeno Bioscience, outside the submitted work. All other authors report no conflicts of interest.",

year = "2022",

month = aug,

day = "1",

doi = "10.1093/ajcn/nqac163",

language = "English",

volume = "116",

pages = "614--616",

journal = "American Journal of Clinical Nutrition",

issn = "0002-9165",

number = "2",

}

TY - JOUR

T1 - Reply to G Taubes, MI Friedman, and V Torres-Carot et al.

AU - Hall, Kevin D.

AU - Farooqi, I. Sadaf

AU - Friedman, Jeffery M.

AU - Klein, Samuel

AU - Loos, Ruth J.F.

AU - Mangelsdorf, David J.

AU - O’Rahilly, Stephen

AU - Ravussin, Eric

AU - Redman, Leanne M.

AU - Ryan, Donna H.

AU - Speakman, John R.

AU - Tobias, Deirdre K.

N1 - Funding Information: Supported by NIH grant 1ZIADK013037 (to KDH). KDH has participated in several debates with David S Ludwig on theories of obesity and has received funding from the Nutrition Science Initiative to test predictions of the CIM. JMF reports royalty payments for leptin for the treatment of lipodystrophy. SK serves as a scientific consultant for Altimmune, Janssen, and B2M and has a sponsored research agreement with Janssen. SOR receives remuneration for scientific advice from Pfizer, AstraZeneca, and ThirdRock Ventures. DHR reports personal fees from Altimmune, Amgen, Gila Therapeutics, Phenomix, Quintiles, Rhythm, YSOPIA, Zealand, Lilly, and Wondr Health, and Roman Health, and personal fees and nonfinancial support from Boeringer Ingelheim, Calibrate, Epitomee, IFA Celtic, Janssen, Novo Nordisk, real appeal (United Health Care), Sanofi, Scientific Intake, and Xeno Bioscience, outside the submitted work. All other authors report no conflicts of interest.

PY - 2022/8/1

Y1 - 2022/8/1

UR - https://www.scopus.com/pages/publications/85135596778

U2 - 10.1093/ajcn/nqac163

DO - 10.1093/ajcn/nqac163

M3 - Letter

C2 - 35675318

AN - SCOPUS:85135596778

SN - 0002-9165

VL - 116

SP - 614

EP - 616

JO - American Journal of Clinical Nutrition

JF - American Journal of Clinical Nutrition

IS - 2

ER -

Reply to G Taubes, MI Friedman, and V Torres-Carot et al.

Access to Document

Other files and links

Cite this